Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: CRVS corvuspharma.com
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK (interleukin-2-inducible T cell kinase) inhibitors as a new approach to immunotherapy for immune diseases and cancer. Its lead product candidate, soquelitinib, is an oral, selective ITK inhibitor being evaluated in a registrational Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (PTCL) and a Phase 2 trial for atopic dermatitis. The company's pipeline extends to planned studies in hidradenitis suppurativa, asthma, and autoimmune lymphoproliferative syndrome (ALPS), as well as next-generation ITK inhibitor preclinical candidates. Corvus holds a 49% equity stake in Angel Pharmaceuticals, a partner developing soquelitinib and other Corvus-licensed candidates in China. The company generates no product revenue and is funded through equity financings. Updated
Penny stocks captivate investors with their low prices. The allure of controlling large numbers of shares for relatively very little money, and potentially generating explosive gains if their stocks move just a…
Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Lee Jackson Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.
Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Avaya, Canopy Growth, Corsair Gaming, Skyworks Solutions and Virgin Galactic.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK (interleukin-2-inducible T cell kinase) inhibitors as a new approach to immunotherapy for immune diseases and cancer.
The Wall Street consensus 12-month price target for CRVS is $31.50.
